Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TelyRx HoldingsTELYF +1.62%12 Equity-to-Asset is 0.35 as of Jun. 2026. GuruFocus rates TELYF with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 687 Healthcare Providers & Services companies, TelyRx Holdings ranks worse than 65.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. TelyRx Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $10.91 Mil. TelyRx Holdings's Total Assets for the quarter that ended in Jun. 2026 was $30.87 Mil.
Therefore, TelyRx Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.35.
The historical rank and industry rank for TelyRx Holdings's Equity-to-Asset or its related term are showing as below:
TELYF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.86 Med: -0.26 Max: 0.41
Current: 0.35
During the past 3 years, the highest Equity to Asset Ratio of TelyRx Holdings was 0.41. The lowest was -0.86. And the median was -0.26.
TELYF's Equity-to-Asset is ranked worse than 65.94% of 687
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs TELYF: 0.35
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
TelyRx Holdings Equity-to-Asset Related Terms
TelyRx Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for TelyRx Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, TelyRx Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TelyRx Holdings Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TelyRx Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where TelyRx Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
TelyRx Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TelyRx Holdings (TELYF) has a Equity-to-Asset of 0.35 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TelyRx Holdings and its competitors. According to the industry distribution chart, TelyRx Holdings ranks #453 out of 687 companies in the Healthcare Providers & Services industry, placing it in the top 65.9%.
Is TelyRx Holdings' Equity-to-Asset too high?
TelyRx Holdings' current Equity-to-Asset is 0.35. The Healthcare Providers & Services industry median Equity-to-Asset is 0.48. TelyRx Holdings' value of 0.35 is 27.1% below this industry median. Based on the distribution chart, TelyRx Holdings ranks #453 out of 687 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' Equity-to-Asset compare to ?
According to the Healthcare Providers & Services industry distribution chart, TelyRx Holdings ranks #453 out of 687 companies for Equity-to-Asset. This places TelyRx Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.48. TelyRx Holdings' value of 0.35 is 27.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TelyRx Holdings's current Equity-to-Asset of 0.35 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TelyRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TelyRx Holdings's current Equity-to-Asset is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TELYF) has a current Equity-to-Asset of 0.35. The current Equity-to-Asset is 0.35 and 27.1% below the Healthcare Providers & Services industry median of 0.48. TelyRx Holdings' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For TelyRx Holdings (TELYF), the current Equity-to-Asset is 0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score
Get the complete analysis for TELYF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELYF has been successfully added to your 
